Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

Valneva

Status and phase: Completed; Phase 2

Conditions: Chronic Hepatitis C

Treatments: Biological: IC41

Study type: Interventional

Funder types: Industry

Identifiers

NCT00602784

IC41-201

Details and patient eligibility

About

The objectives are

1. to determine the immunological profile (CD4+, CD8+ cells, DTH) induced by immunization with HCV antigen peptide vaccine with polyarginine.
2. to document virological (HCV-RNA) and biochemical (ALT) responses following immunization with HCV antigen peptide vaccine with polyarginine.
3. to assess the safety of immunization with HCV antigen peptide vaccine with polyarginine.

Full description

This is a double blind, randomized, parallel group, controlled, multicenter phase II study.

60 patients will be enrolled and assigned to one of the 5 dose or control groups. Each study group will include 8 patients.

Each patient will receive a total of 6 injections according to the dose of the assigned study group. The injections will be administered subcutaneously in the upper arm once every four weeks for 5 months, i.e. at days 1, 29, 57, 85, 113 and 141.

The volume of each injection will be 0.5 ml in all groups.

Enrollment: 66 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of chronic hepatitis C
• Non-response to or relapse from primary standard HCV therapy
• HLA A2 positive
• HCV-RNA positive
• HCV antibodies positive
• Liver biopsy within 30 months prior to inclusion
• Hematology and biochemistry laboratory results within the limits normally expected for the patient population (liver values maximal 5 times the upper limit of normal)
• Male and female
• From 18 to 65 years
• Written informed consent obtained prior to study entry

Exclusion criteria

• Any degree of liver cirrhosis or fibrosis of Ishak score ≥ 4 (for grading table, see APPENDIX 2: The Ishak Modified Hepatic Activity Index (HAI))
• Any liver disease other than hepatitis C
• History of autoimmune disease
• Immunodeficiency including post-organ-transplantation
• HIV infection
• Immunosuppressive therapy
• Any acute infections within 4 weeks prior to inclusion
• History of severe hypersensitivity reactions, anaphylaxis or atopy
• Diabetes mellitus, severe cardiopulmonary disorders, history of malignancy in the past 5 years
• Active or passive vaccination within 2 months prior to enrolment, and concomitant vaccination throughout the study period
• Pregnancy or lactation
• Unreliable contraception
• Alcohol consumption
• Drug abuse or addiction within 12 months prior to inclusion
• Participation in a methadone program
• Participation in another study within 1 month prior to enrolment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

66 participants in 5 patient groups

IC41-B-01/02

Experimental group

Description:

peptide dose 0.00 mg, polyarginine dose 2.00 mg

Treatment:

Biological: IC41

IC41-C-01/02

Experimental group

Description:

peptide dose: 5.00 mg, polyarginine dose: 0.00 mg

Treatment:

Biological: IC41

IC41-G-01/02

Experimental group

Description:

peptide dose: 2.50 mg, polyarginine dose: 1.25 mg

Treatment:

Biological: IC41

IC41-H-01/02

Experimental group

Description:

peptide dose: 2.50 mg, polyarginine dose: 2.00 mg

Treatment:

Biological: IC41

IC41-K-01/02

Experimental group

Description:

peptide dose: 5.00 mg, polyarginine dose: 2.00 mg

Treatment:

Biological: IC41